April 11, 2010

Hallucinogens Have Doctors Tuning In Again
By JOHN TIERNEY
NY Times

http://www.nytimes.com/2010/04/12/science/12psychedelics.html?hp=&pagewanted=print


As a retired clinical psychologist, Clark Martin was well acquainted 
with traditional treatments for depression, but his own case seemed 
untreatable as he struggled through chemotherapy and other grueling 
regimens for kidney cancer. Counseling seemed futile to him. So did the 
antidepressant pills he tried.

Nothing had any lasting effect until, at the age of 65, he had his first 
psychedelic experience. He left his home in Vancouver, Wash., to take 
part in an experiment at Johns Hopkins medical school involving 
psilocybin, the psychoactive ingredient found in certain mushrooms.

Scientists are taking a new look at hallucinogens, which became taboo 
among regulators after enthusiasts like Timothy Leary promoted them in 
the 1960s with the slogan “Turn on, tune in, drop out.” Now, using 
rigorous protocols and safeguards, scientists have won permission to 
study once again the drugs’ potential for treating mental problems and 
illuminating the nature of consciousness.

After taking the hallucinogen, Dr. Martin put on an eye mask and 
headphones, and lay on a couch listening to classical music as he 
contemplated the universe.

“All of a sudden, everything familiar started evaporating,” he recalled. 
“Imagine you fall off a boat out in the open ocean, and you turn around, 
and the boat is gone. And then the water’s gone. And then you’re gone.”

Today, more than a year later, Dr. Martin credits that six-hour 
experience with helping him overcome his depression and profoundly 
transforming his relationships with his daughter and friends. He ranks 
it among the most meaningful events of his life, which makes him a 
fairly typical member of a growing club of experimental subjects.

Researchers from around the world are gathering this week in San Jose, 
Calif., for the largest conference on psychedelic science held in the 
United States in four decades. They plan to discuss studies of 
psilocybin and other psychedelics for treating depression in cancer 
patients, obsessive-compulsive disorder, end-of-life anxiety, 
post-traumatic stress disorder and addiction to drugs or alcohol.

The results so far are encouraging but also preliminary, and researchers 
caution against reading too much into these small-scale studies. They do 
not want to repeat the mistakes of the 1960s, when some 
scientists-turned-evangelists exaggerated their understanding of the 
drugs’ risks and benefits.

Because reactions to hallucinogens can vary so much depending on the 
setting, experimenters and review boards have developed guidelines to 
set up a comfortable environment with expert monitors in the room to 
deal with adverse reactions. They have established standard protocols so 
that the drugs’ effects can be gauged more accurately, and they have 
also directly observed the drugs’ effects by scanning the brains of 
people under the influence of hallucinogens.

Scientists are especially intrigued by the similarities between 
hallucinogenic experiences and the life-changing revelations reported 
throughout history by religious mystics and those who meditate. These 
similarities have been identified in neural imaging studies conducted by 
Swiss researchers and in experiments led by Roland Griffiths, a 
professor of behavioral biology at Johns Hopkins.

In one of Dr. Griffiths’s first studies, involving 36 people with no 
serious physical or emotional problems, he and colleagues found that 
psilocybin could induce what the experimental subjects described as a 
profound spiritual experience with lasting positive effects for most of 
them. None had had any previous experience with hallucinogens, and none 
were even sure what drug was being administered.

To make the experiment double-blind, neither the subjects nor the two 
experts monitoring them knew whether the subjects were receiving a 
placebo, psilocybin or another drug like Ritalin, nicotine, caffeine or 
an amphetamine. Although veterans of the ’60s psychedelic culture may 
have a hard time believing it, Dr. Griffiths said that even the monitors 
sometimes could not tell from the reactions whether the person had taken 
psilocybin or Ritalin.

The monitors sometimes had to console people through periods of anxiety, 
Dr. Griffiths said, but these were generally short-lived, and none of 
the people reported any serious negative effects. In a survey conducted 
two months later, the people who received psilocybin reported 
significantly more improvements in their general feelings and behavior 
than did the members of the control group.

The findings were repeated in another follow-up survey, taken 14 months 
after the experiment. At that point most of the psilocybin subjects once 
again expressed more satisfaction with their lives and rated the 
experience as one of the five most meaningful events of their lives.

Since that study, which was published in 2008, Dr. Griffiths and his 
colleagues have gone on to give psilocybin to people dealing with cancer 
and depression, like Dr. Martin, the retired psychologist from 
Vancouver. Dr. Martin’s experience is fairly typical, Dr. Griffiths 
said: an improved outlook on life after an experience in which the 
boundaries between the self and others disappear.

In interviews, Dr. Martin and other subjects described their egos and 
bodies vanishing as they felt part of some larger state of consciousness 
in which their personal worries and insecurities vanished. They found 
themselves reviewing past relationships with lovers and relatives with a 
new sense of empathy.

“It was a whole personality shift for me,” Dr. Martin said. “I wasn’t 
any longer attached to my performance and trying to control things. I 
could see that the really good things in life will happen if you just 
show up and share your natural enthusiasms with people. You have a 
feeling of attunement with other people.”

The subjects’ reports mirrored so closely the accounts of religious 
mystical experiences, Dr. Griffiths said, that it seems likely the human 
brain is wired to undergo these “unitive” experiences, perhaps because 
of some evolutionary advantage.

“This feeling that we’re all in it together may have benefited 
communities by encouraging reciprocal generosity,” Dr. Griffiths said. 
“On the other hand, universal love isn’t always adaptive, either.”

Although federal regulators have resumed granting approval for 
controlled experiments with psychedelics, there has been little public 
money granted for the research, which is being conducted at Hopkins, the 
University of Arizona; Harvard; New York University; the University of 
California, Los Angeles; and other places.

The work has been supported by nonprofit groups like the Heffter 
Research Institute and MAPS, the Multidisciplinary Association for 
Psychedelic Studies.

“There’s this coming together of science and spirituality,” said Rick 
Doblin, the executive director of MAPS. “We’re hoping that the 
mainstream and the psychedelic community can meet in the middle and 
avoid another culture war. Thanks to changes over the last 40 years in 
the social acceptance of the hospice movement and yoga and meditation, 
our culture is much more receptive now, and we’re showing that these 
drugs can provide benefits that current treatments can’t.”

Researchers are reporting preliminary success in using psilocybin to 
ease the anxiety of patients with terminal illnesses. Dr. Charles S. 
Grob, a psychiatrist who is involved in an experiment at U.C.L.A., 
describes it as “existential medicine” that helps dying people overcome 
fear, panic and depression.

“Under the influences of hallucinogens,” Dr. Grob writes, “individuals 
transcend their primary identification with their bodies and experience 
ego-free states before the time of their actual physical demise, and 
return with a new perspective and profound acceptance of the life 
constant: change.”

-- 
================================
George Antunes, Political Science Dept
University of Houston; Houston, TX 77204
Voice: 713-743-3923  Fax: 713-743-3927
Mail: antunes at uh dot edu

_______________________________________________
Medianews mailing list
[email protected]
http://lists.etskywarn.net/mailman/listinfo/medianews

Reply via email to